Abbott (ABT) announced the FDA has approved the Aveir single-chamber leadless pacemaker for the treatment of patients in the U.S. with slow heart rhythms. The Aveir leadless pacemaker is implanted directly inside the heart's right ventricle via a minimally invasive procedure to treat slower-than-normal heart rates. The approval is supported by data from the global LEADLESS II phase 2 investigational device exemption study evaluating Aveir VR in patients with certain abnormal heart rhythms.
"The Aveir VR leadless pacemaker was designed to make the implantation and retrieval processes as seamless as possible for physicians and provide improvements over existing options," said Randel Woodgrift, senior vice president, Cardiac Rhythm Management, Abbott.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.